Organon & Co (OGN)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $3.65B
Last updated: Nov 17, 2026 at 11:06 AM ET
Organon & Co (OGN) Earnings: Report Dates and Results
Organon (OGN) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, Organon reported EPS of $0.88, below the $0.95 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
OGN has an expected report date of Feb 10, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 27.0% above the $0.63 reported for the quarter ended Dec 31, 2025.
OGN Earnings Call
The latest OGN earnings call transcript on file is labeled 2025Q4.
Read the 2025Q4 transcriptEarnings History
Of the 23 quarters below that had an estimate, OGN beat 15 and missed 8. Revenue for the quarter ended Sep 30, 2026 was $1.57B, down 1.9% from $1.60B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.88 | $0.95 | $0.88 - $1.05 | -7.37% | Miss | -12.9% | 3 | 0 up, 0 down | Oct 30, 2026 | $1.57B |
| Jun 30, 2026 | $0.80 | $0.85 | N/A | -5.88% | Miss | -20.0% | 1 | 0 up, 0 down | Jul 31, 2026 | $1.56B |
| Mar 31, 2026 | $0.71 | $0.85 | $0.77 - $0.95 | -16.47% | Miss | -30.4% | 6 | 2 up, 1 down | Apr 30, 2026 | $1.46B |
| Dec 31, 2025 | $0.63 | $0.73 | $0.62 - $0.81 | -13.70% | Miss | -30.0% | 7 | 0 up, 1 down | Feb 12, 2026 | $1.51B |
| Sep 30, 2025 | $1.01 | $0.93 | $0.89 - $0.97 | +8.60% | Beat | +16.1% | 5 | 1 up, 1 down | Nov 10, 2025 | $1.60B |
| Jun 30, 2025 | $1.00 | $0.94 | $0.90 - $0.99 | +6.38% | Beat | -10.7% | 5 | 1 up, 0 down | Aug 5, 2025 | $1.59B |
| Mar 31, 2025 | $1.02 | $0.89 | $0.86 - $0.94 | +14.61% | Beat | -16.4% | 5 | 0 up, 1 down | May 1, 2025 | $1.51B |
| Dec 31, 2024 | $0.90 | $0.87 | $0.82 - $0.93 | +3.45% | Beat | +2.3% | 7 | 1 up, 1 down | Feb 13, 2025 | $1.59B |
| Sep 30, 2024 | $0.87 | $0.90 | $0.78 - $1.11 | -3.33% | Miss | 0.0% | 7 | 0 up, 2 down | Oct 31, 2024 | $1.58B |
| Jun 30, 2024 | $1.12 | $1.08 | $0.93 - $1.24 | +3.70% | Beat | -14.5% | 7 | 0 up, 2 down | Aug 6, 2024 | $1.61B |
| Mar 31, 2024 | $1.22 | $0.93 | $0.88 - $1.22 | +31.18% | Beat | +13.0% | 6 | 4 up, 1 down | May 2, 2024 | $1.62B |
| Dec 31, 2023 | $0.88 | $0.83 | $0.68 - $1.07 | +6.02% | Beat | +8.6% | 7 | 2 up, 0 down | Feb 15, 2024 | $1.60B |
| Sep 30, 2023 | $0.87 | $1.06 | $1.04 - $1.10 | -17.92% | Miss | -34.1% | 6 | 1 up, 0 down | Nov 2, 2023 | $1.52B |
| Jun 30, 2023 | $1.31 | $0.99 | $0.94 - $1.04 | +32.32% | Beat | +4.8% | 6 | 0 up, 1 down | Aug 8, 2023 | $1.61B |
| Mar 31, 2023 | $1.08 | $1.16 | $1.06 - $1.25 | -6.90% | Miss | -34.5% | 7 | 2 up, 0 down | May 4, 2023 | $1.54B |
| Dec 31, 2022 | $0.81 | $0.90 | $0.74 - $1.03 | -10.00% | Miss | -40.9% | 6 | 1 up, 1 down | Feb 16, 2023 | $1.49B |
| Sep 30, 2022 | $1.32 | $1.10 | $0.92 - $1.39 | +20.00% | Beat | -21.0% | 6 | 0 up, 1 down | Nov 3, 2022 | $1.54B |
| Jun 30, 2022 | $1.25 | $1.19 | N/A | +5.04% | Beat | -27.3% | N/A | 0 up, 1 down | Aug 4, 2022 | $1.58B |
| Mar 31, 2022 | $1.65 | $1.30 | $1.14 - $1.46 | +26.92% | Beat | +4.4% | 6 | 1 up, 1 down | May 5, 2022 | $1.57B |
| Dec 31, 2021 | $1.37 | $1.27 | $1.14 - $1.33 | +7.87% | Beat | N/A | 6 | N/A | Feb 17, 2022 | $1.60B |
| Sep 30, 2021 | $1.67 | $1.44 | $1.29 - $1.71 | +15.97% | Beat | N/A | 6 | 2 up, 0 down | Nov 11, 2021 | $1.60B |
| Jun 30, 2021 | $1.72 | $1.43 | $1.26 - $1.57 | +20.28% | Beat | N/A | 3 | N/A | Aug 12, 2021 | $1.59B |
| Mar 31, 2021 | $1.58 | $1.52 | N/A | +3.95% | Beat | N/A | N/A | N/A | Jun 21, 2021 | $1.51B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $3.66, down 10.9% from the year before. It was $6.34 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $3.66 | -10.9% |
| Dec 31, 2024 | $4.11 | N/A |
| Dec 31, 2023 | $4.14 | -17.7% |
| Dec 31, 2022 | $5.03 | -20.7% |
| Dec 31, 2021 | $6.34 | N/A |
Earnings Calls
The 7 most recent earnings calls are listed below; the latest, 2025Q4 for the period ended Dec 31, 2025, runs about 5,300 words across 12 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2025Q4 | Dec 31, 2025 | 5,269 | 12 | |
| 2025Q3 | Sep 30, 2025 | 6,865 | 12 | |
| 2025Q2 | Jun 30, 2025 | 5,974 | 11 | |
| 2025Q1 | Mar 31, 2025 | 4,483 | 10 | |
| 2024Q4 | Dec 31, 2024 | 8,493 | 12 | |
| 2024Q3 | Sep 30, 2024 | 5,764 | 9 | |
| 2024Q2 | Jun 30, 2024 | 7,158 | 10 |
2025Q4 Earnings Call
Opening remarks
Jennifer Halchak Vice President, Investor Relations Thank you, operator. Good morning, everyone. With me today are Joe Morrissey, Organon's Interim Chief Executive Officer; and Matt Walsh, our Chief Financial Officer; Carrie Cox, Organon's Board Chair; and Juan Camilo Arjona Ferreira, Organon's Head of R&D, will also be joining for the Q&A portion of this call. Today, we are referencing a presentation that will be visible during this call for those of you on our webcast. This presentation will also be available following this call on the Events and Presentations section of our Organon Investor Relations website. Please reference Slides 2 and 3 for a couple of brief reminders. I would like to caution listeners that certain information discussed by management during this call will include forward-looking statements. Forward-looking statements can be identified because they do not relate strictly to historical or current facts and use words such as potential, should, will, continue, expects, believe, future, estimates, believes, outlook and other words of similar meaning. Actual results could differ materially from those stated or implied by forward-looking statements due to risks and uncertainties associated with the company's business, which are discussed in the company's filings with the Securities and Exchange Commission. This includes our most recent Form 10-K and Forms 10-Q and those amended forms. These statements are based on information as of today, February 12, 2026 and except as required by law, Organon undertakes no obligation to update or revise any of these forward-looking statements. In addition, we will discuss certain non-GAAP financial measures on this call, which should be considered a supplement to and not a substitute for financial measures prepared in accordance with GAAP. Descriptions of these measures and reconciliations to the comparable GAAP measures are included in today's earnings press release and conference call presentation, both of which are available on our Investor Relations website and have been furnished to the SEC on the current report on Form 8-K. I note that while our full year 2026 guidance measures other than revenue are provided on a non-GAAP basis, Organon does not provide GAAP financial measures on a forward-looking basis because we cannot predict with reasonable certainty and without unreasonable effort, the ultimate outcome of legal proceedings, unusual gains and losses, the occurrence of matters creating GAAP tax impacts and acquisition-related expenses. These items are uncertain, depend on various factors and could be material to our results computed in accordance with GAAP. I'd now like to turn the call over to Joe Morrissey.
Joseph Morrissey Interim CEO Thank you, Jen. Beginning on Slide 4. In 2025, Organon delivered $6.2 billion in revenue and $1.9 billion of adjusted EBITDA. Revenue was down 3% on both a reported and ex-exchange basis.
Frequently Asked Questions About OGN
When is Organon's next earnings date?
Organon's next earnings report is expected for Feb 10, 2027.
Did OGN beat earnings estimates last quarter?
No. Organon reported EPS of $0.88 for the quarter ended Sep 30, 2026, below the $0.95 estimate by 7.37%.
What EPS do analysts expect from OGN next quarter?
The consensus EPS estimate for Organon for the quarter ending Dec 31, 2026 is $0.80 from 9 analysts, with estimates from $0.64 to $0.97.
How often does OGN beat earnings estimates?
Organon beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -1.30%.
OGN pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors